BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Neidert MC, Kowalewski DJ, Silginer M, Kapolou K, Backert L, Freudenmann LK, Peper JK, Marcu A, Wang SS, Walz JS, Wolpert F, Rammensee HG, Henschler R, Lamszus K, Westphal M, Roth P, Regli L, Stevanović S, Weller M, Eisele G. The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. Acta Neuropathol 2018;135:923-38. [PMID: 29557506 DOI: 10.1007/s00401-018-1836-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Marconato M, Maringer Y, Walz JS, Nelde A, Heitmann JS. Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease Outcome. Cancers 2022;14:4659. [DOI: 10.3390/cancers14194659] [Reference Citation Analysis]
2 Quijano-Rubio C, Silginer M, Weller M. CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner. Cell Death Discov 2022;8:341. [PMID: 35906203 DOI: 10.1038/s41420-022-01133-y] [Reference Citation Analysis]
3 Alarcon NO, Jaramillo M, Mansour HM, Sun B. Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms. Pharmaceutics 2022;14:1448. [DOI: 10.3390/pharmaceutics14071448] [Reference Citation Analysis]
4 Nelde A, Flötotto L, Jürgens L, Szymik L, Hubert E, Bauer J, Schliemann C, Kessler T, Lenz G, Rammensee HG, Walz JS, Wethmar K. Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens. Cell Mol Life Sci 2022;79:171. [PMID: 35239002 DOI: 10.1007/s00018-022-04145-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Marcu A, Schlosser A, Keupp A, Trautwein N, Johann P, Wölfl M, Lager J, Monoranu CM, Walz JS, Henkel LM, Krauß J, Ebinger M, Schuhmann M, Thomale UW, Pietsch T, Klinker E, Schlegel PG, Oyen F, Reisner Y, Rammensee HG, Eyrich M. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. J Immunother Cancer 2021;9:e003404. [PMID: 34599019 DOI: 10.1136/jitc-2021-003404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ramarathinam SH, Purcell AW. Proteomics special issue: Precision immunology and oncology. Proteomics 2021;21:e2000159. [PMID: 34510736 DOI: 10.1002/pmic.202000159] [Reference Citation Analysis]
7 Nelde A, Maringer Y, Bilich T, Salih HR, Roerden M, Heitmann JS, Marcu A, Bauer J, Neidert MC, Denzlinger C, Illerhaus G, Aulitzky WE, Rammensee HG, Walz JS. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia. Front Immunol 2021;12:705974. [PMID: 34305947 DOI: 10.3389/fimmu.2021.705974] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wang Z, Zhang H, Xu S, Liu Z, Cheng Q. The adaptive transition of glioblastoma stem cells and its implications on treatments. Signal Transduct Target Ther 2021;6:124. [PMID: 33753720 DOI: 10.1038/s41392-021-00491-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
9 Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells 2021;10:621. [PMID: 33799798 DOI: 10.3390/cells10030621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
10 Chen L, Qin D, Guo X, Wang Q, Li J. Putting Proteomics Into Immunotherapy for Glioblastoma. Front Immunol 2021;12:593255. [PMID: 33708196 DOI: 10.3389/fimmu.2021.593255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Nelde A, Rammensee HG, Walz JS. The Peptide Vaccine of the Future. Mol Cell Proteomics 2021;20:100022. [PMID: 33583769 DOI: 10.1074/mcp.R120.002309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
12 Forlani G, Michaux J, Pak H, Huber F, Marie Joseph EL, Ramia E, Stevenson BJ, Linnebacher M, Accolla RS, Bassani-Sternberg M. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens. Mol Cell Proteomics 2021;20:100032. [PMID: 33592498 DOI: 10.1074/mcp.RA120.002201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Teck AT, Urban S, Quass P, Nelde A, Schuster H, Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S. Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother 2020;69:1217-27. [PMID: 32157447 DOI: 10.1007/s00262-020-02519-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ghantasala S, Gollapalli K, Epari S, Moiyadi A, Srivastava S. Glioma tumor proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics 2020;17:221-32. [PMID: 32067544 DOI: 10.1080/14789450.2020.1731310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mohme M, Neidert MC. Tumor-Specific T Cell Activation in Malignant Brain Tumors. Front Immunol 2020;11:205. [PMID: 32117316 DOI: 10.3389/fimmu.2020.00205] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
16 Ghosh M, Gauger M, Marcu A, Nelde A, Denk M, Schuster H, Rammensee HG, Stevanović S. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies. Mol Cell Proteomics 2020;19:432-43. [PMID: 31937595 DOI: 10.1074/mcp.C119.001652] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
17 Ternette N, Purcell AW. Immunopeptidomics Special Issue. Proteomics 2018;18:e1800145. [PMID: 29949244 DOI: 10.1002/pmic.201800145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, Kumasaka D, Pierce RH, Weller M, Finer M, Quéva C, Glorioso JC, Houghton AM, Holland EC. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. JCI Insight 2019;4:128217. [PMID: 31292299 DOI: 10.1172/jci.insight.128217] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
19 Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou C, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee H, Stevanović S, Walz JS. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 2019;133:550-65. [DOI: 10.1182/blood-2018-07-866830] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 10.7] [Reference Citation Analysis]
20 Shieh M, Chitnis N, Monos D. Human Leukocyte Antigen and Disease Associations. Clinics in Laboratory Medicine 2018;38:679-93. [DOI: 10.1016/j.cll.2018.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Santambrogio L, Rammensee HG. Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome. Immunogenetics 2019;71:203-16. [PMID: 30343358 DOI: 10.1007/s00251-018-1093-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Freudenmann LK, Marcu A, Stevanović S. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology 2018;154:331-45. [PMID: 29658117 DOI: 10.1111/imm.12936] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]